Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 39

1.

Chemical and Molecular Approach to Tumor Metastases.

Bergamo A, Sava G.

Int J Mol Sci. 2018 Mar 14;19(3). pii: E843. doi: 10.3390/ijms19030843.

2.

Influence of components of tumour microenvironment on the response of HCT-116 colorectal cancer to the ruthenium-based drug NAMI-A.

Bergamo A, Pelillo C, Chambery A, Sava G.

J Inorg Biochem. 2017 Mar;168:90-97. doi: 10.1016/j.jinorgbio.2016.11.031. Epub 2016 Dec 2.

PMID:
28064102
3.

Pharmacological Activities of Ruthenium Complexes Related to Their NO Scavenging Properties.

Castellarin A, Zorzet S, Bergamo A, Sava G.

Int J Mol Sci. 2016 Aug 2;17(8). pii: E1254. doi: 10.3390/ijms17081254.

4.

Inhibition of adhesion, migration and of α5β1 integrin in the HCT-116 colorectal cancer cells treated with the ruthenium drug NAMI-A.

Pelillo C, Mollica H, Eble JA, Grosche J, Herzog L, Codan B, Sava G, Bergamo A.

J Inorg Biochem. 2016 Jul;160:225-35. doi: 10.1016/j.jinorgbio.2016.02.025. Epub 2016 Feb 27.

PMID:
26961176
5.

RNA-seq analysis of the whole transcriptome of MDA-MB-231 mammary carcinoma cells exposed to the antimetastatic drug NAMI-A.

Bergamo A, Gerdol M, Lucafò M, Pelillo C, Battaglia M, Pallavicini A, Sava G.

Metallomics. 2015 Oct;7(10):1439-50. doi: 10.1039/c5mt00081e. Epub 2015 Sep 4.

PMID:
26338673
6.

Phototoxic Activity and DNA Interactions of Water-Soluble Porphyrins and Their Rhenium(I) Conjugates.

Mion G, Gianferrara T, Bergamo A, Gasser G, Pierroz V, Rubbiani R, Vilar R, Leczkowska A, Alessio E.

ChemMedChem. 2015 Nov;10(11):1901-14. doi: 10.1002/cmdc.201500288. Epub 2015 Sep 2.

PMID:
26332425
7.

Colorectal Cancer Metastases Settle in the Hepatic Microenvironment Through α5β1 Integrin.

Pelillo C, Bergamo A, Mollica H, Bestagno M, Sava G.

J Cell Biochem. 2015 Oct;116(10):2385-96. doi: 10.1002/jcb.25189.

PMID:
25857463
8.

Linking the future of anticancer metal-complexes to the therapy of tumour metastases.

Bergamo A, Sava G.

Chem Soc Rev. 2015 Dec 21;44(24):8818-35. doi: 10.1039/c5cs00134j. Epub 2015 Mar 26. Review.

PMID:
25812154
9.

Preclinical combination therapy of the investigational drug NAMI-A(+) with doxorubicin for mammary cancer.

Bergamo A, Riedel T, Dyson PJ, Sava G.

Invest New Drugs. 2015 Feb;33(1):53-63. doi: 10.1007/s10637-014-0175-5. Epub 2014 Oct 23.

PMID:
25338748
10.

Modulation of activity of known cytotoxic ruthenium(III) compound (KP418) with hampered transmembrane transport in electrochemotherapy in vitro and in vivo.

Hudej R, Miklavcic D, Cemazar M, Todorovic V, Sersa G, Bergamo A, Sava G, Martincic A, Scancar J, Keppler BK, Turel I.

J Membr Biol. 2014 Dec;247(12):1239-51. doi: 10.1007/s00232-014-9696-2. Epub 2014 Jun 24.

PMID:
24957014
11.

Towards matched pairs of porphyrin-Re(I) /(99m) Tc(I) conjugates that combine photodynamic activity with fluorescence and radio imaging.

Gianferrara T, Spagnul C, Alberto R, Gasser G, Ferrari S, Pierroz V, Bergamo A, Alessio E.

ChemMedChem. 2014 Jun;9(6):1231-7. doi: 10.1002/cmdc.201300501. Epub 2014 Feb 23.

PMID:
24678041
12.

Novel water-soluble (99m)Tc(I)/Re(I)-porphyrin conjugates as potential multimodal agents for molecular imaging.

Spagnul C, Alberto R, Gasser G, Ferrari S, Pierroz V, Bergamo A, Gianferrara T, Alessio E.

J Inorg Biochem. 2013 May;122:57-65. doi: 10.1016/j.jinorgbio.2012.12.016. Epub 2013 Jan 9.

PMID:
23474539
13.

Targeted therapy vs. DNA-adduct formation-guided design: thoughts about the future of metal-based anticancer drugs.

Sava G, Jaouen G, Hillard EA, Bergamo A.

Dalton Trans. 2012 Jul 21;41(27):8226-34. doi: 10.1039/c2dt30075c. Epub 2012 May 22. Review.

PMID:
22614531
14.

New half sandwich Ru(II) coordination compounds for anticancer activity.

Bratsos I, Mitri E, Ravalico F, Zangrando E, Gianferrara T, Bergamo A, Alessio E.

Dalton Trans. 2012 Jun 28;41(24):7358-71. doi: 10.1039/c2dt30654a. Epub 2012 May 11.

PMID:
22580919
15.

CDK1 hyperphosphorylation maintenance drives the time-course of G2-M cell cycle arrest after short treatment with NAMI-A in Kb cells.

Bergamo A, Delfino R, Casarsa C, Sava G.

Anticancer Agents Med Chem. 2012 Oct 1;12(8):949-58.

PMID:
22263785
16.

New half sandwich-type Ru(II) coordination compounds characterized by the fac-Ru(dmso-S)3 fragment: influence of the face-capping group on the chemical behavior and in vitro anticancer activity.

Bratsos I, Simonin C, Zangrando E, Gianferrara T, Bergamo A, Alessio E.

Dalton Trans. 2011 Oct 7;40(37):9533-43. doi: 10.1039/c1dt11043h. Epub 2011 Aug 19.

PMID:
21853191
17.

Metal-based antitumour drugs in the post-genomic era: what comes next?

Sava G, Bergamo A, Dyson PJ.

Dalton Trans. 2011 Sep 28;40(36):9069-75. doi: 10.1039/c1dt10522a. Epub 2011 Jul 4.

PMID:
21725573
18.

Ruthenium anticancer compounds: myths and realities of the emerging metal-based drugs.

Bergamo A, Sava G.

Dalton Trans. 2011 Aug 21;40(31):7817-23. doi: 10.1039/c0dt01816c. Epub 2011 Jun 1.

PMID:
21629963
19.

Ruthenium-porphyrin conjugates with cytotoxic and phototoxic antitumor activity.

Gianferrara T, Bergamo A, Bratsos I, Milani B, Spagnul C, Sava G, Alessio E.

J Med Chem. 2010 Jun 24;53(12):4678-90. doi: 10.1021/jm1002588.

PMID:
20491441
20.

Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound.

Bergamo A, Masi A, Dyson PJ, Sava G.

Int J Oncol. 2008 Dec;33(6):1281-9.

PMID:
19020762

Supplemental Content

Loading ...
Support Center